Wave Life Sciences (NASDAQ:WVE) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Tuesday.

Several other brokerages also recently commented on WVE. Leerink Swann restated an “outperform” rating and issued a $53.00 target price (up previously from $42.00) on shares of Wave Life Sciences in a research note on Wednesday, November 15th. Zacks Investment Research upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. Finally, Mizuho set a $34.00 target price on shares of Wave Life Sciences and gave the company a “buy” rating in a research note on Saturday, October 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $41.60.

Shares of Wave Life Sciences (NASDAQ:WVE) opened at $32.55 on Tuesday. The stock has a market cap of $932.35, a price-to-earnings ratio of -9.19 and a beta of 0.75. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.50 and a quick ratio of 11.50. Wave Life Sciences has a 52 week low of $15.15 and a 52 week high of $39.70.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.03. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.77 million. Wave Life Sciences had a negative net margin of 3,338.68% and a negative return on equity of 59.52%. research analysts expect that Wave Life Sciences will post -3.76 EPS for the current year.

In related news, insider Chandra Vargeese sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $35.00, for a total value of $52,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ra Capital Management, Llc acquired 423,398 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was acquired at an average price of $23.34 per share, with a total value of $9,882,109.32. The disclosure for this purchase can be found here. Insiders own 53.00% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Nationwide Fund Advisors grew its position in shares of Wave Life Sciences by 58.1% in the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock valued at $125,000 after purchasing an additional 2,470 shares during the period. The Manufacturers Life Insurance Company boosted its position in Wave Life Sciences by 71.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after acquiring an additional 3,912 shares during the last quarter. Rhumbline Advisers boosted its position in Wave Life Sciences by 62.3% during the 2nd quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock worth $233,000 after acquiring an additional 4,800 shares during the last quarter. Alliancebernstein L.P. acquired a new position in Wave Life Sciences during the 2nd quarter worth approximately $236,000. Finally, New York State Common Retirement Fund boosted its position in Wave Life Sciences by 64.9% during the 2nd quarter. New York State Common Retirement Fund now owns 12,700 shares of the company’s stock worth $236,000 after acquiring an additional 4,999 shares during the last quarter. Institutional investors and hedge funds own 73.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades Wave Life Sciences (WVE) to Hold” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/bidaskclub-downgrades-wave-life-sciences-wve-to-hold/1799612.html.

About Wave Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.